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In human cytomegalovirus (HCMV), the UL128-131A locus plays an essential role in cellular tropism and
spread. Here, we report the complete annotation of the GP129-133 locus from guinea pig cytomegalo-
virus (GPCMV) and the discovery of the UL131A homolog, named GP133. We have found that similar to
HCMV the GP129-133 proteins form a pentamer complex with the GPCMV glycoproteins gH and gL. In
addition, we ﬁnd that the GP129-133 proteins play a critical role in entry as the GP129-133 deletion
mutant shows a defect in both endothelial and ﬁbroblast cell entry. Although the GP129-133 deletion
strain can propagate in vitro, we ﬁnd that the deletion fails to spread in vivo. Interestingly, the wildtype
strain can spontaneously give rise to the GP129-133 deletion strain during in vivo spread, suggesting
genetic instability at this locus.
& 2013 Elsevier Inc. All rights reserved.Introduction
Herpesviruses are prevalent animal pathogens, producing a
variety of medical illness and disease. Human cytomegalovirus
(HCMV, species Human herpesvirus 5) is the most common cause
of congenital virus infection. Congenital HCMV infection occurs in
0.2–1% of all births, and causes birth defects and developmental
abnormalities, including sensorineural hearing loss (SHNL) and
developmental delay (Ogawa et al., 2007; Pass, 2002). Animal
models are often valuable for understanding pathogenesis and for
developing therapies for infectious disease, and in the case of
CMV, models are particularly necessary since the species-
speciﬁcity precludes the study of HCMV in laboratory animals
(Powers and Fruh, 2008; Schleiss, 2002). In contrast to murine
CMV (MCMV) and rat CMV (RCMV), guinea pig CMV (GPCMV)
crosses the placenta and causes infection in utero (Schleiss, 2002).
This makes the GPCMV animal model useful for studies on
transplacental transmission of CMV and vaccine development
(Schleiss, 2006, 2007). The only commercially-available GPCMV
strain (strain 22122 from the American Type Culture Collection)
was revealed to be a mixture of two variants: one containing all rights reserved.
ases, Genentech,
, MS 33, South San Francisco,wildtype 1.6 kb locus encoding the homologs of HCMV UL128 and
UL130, GP129 and GP131, respectively, and the other containing a
deletion of this region (Nozawa et al., 2008). A homolog of HCMV
UL131A has not been described. The 1.6 kb locus was shown to be
required for efﬁcient viral growth in animals, but dispensable for
growth in cell culture (Nozawa et al., 2008). However, conclusions
from these prior studies are limited due to the lack of guinea pig-
speciﬁc reagents, such as primary cell lines and antibodies to the
proteins encoded by this locus.
The HCMV gH/gL/UL128/UL130/UL131A complex is required for
viral entry into epithelial cells, endothelial cells, and macrophages,
but not ﬁbroblasts, and is a major antigen of the human neutraliz-
ing immune response (Fouts et al., 2012; Hahn et al., 2004; Wang
et al., 2011; Wang and Shenk, 2005a, 2005b). It is well known that
propagation of HCMV in ﬁbroblasts leads to the instability and
functional loss of the UL128-131A complex (Hahn et al., 2004;
Wang and Shenk, 2005a, 2005b). The HCMV UL128, UL130, and
UL131A proteins form a pentameric complex with glycoprotein H
(gH) and glycoprotein gL (gL) (Ryckman et al., 2008). gH and gL
have been identiﬁed in GPCMV, but it is unknown if these proteins
form a heterodimer (Brady and Schleiss, 1996; Paglino et al., 1999).
Furthermore, it is unknown if gH and gL form an analogous
complex with the aforementioned GP129 and GP131.
In this study, we have conﬁrmed the expression of GP133 and
identiﬁed it as a homolog of HCMV UL131A. In addition, we show
that GP133 can form a pentameric complex with GPCMV gH, gL,
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and ﬁbroblast cell lines, we demonstrate that the GP129-133 locus
serves a role in viral entry into cells. Furthermore, we have found
that, the GP129-133 locus is genetically unstable in vivo leading to
a mixture of wildtype and a mutant with a deletion of this region.Fig. 1. Immunoﬂuorescence of GPCMV-infected guinea pig-primary ﬁbroblast cells.
(A) Detection of gB using the anti-GPCMV gB monoclonal antibody, 29-29, during
infection at 18, 24, and 48 h post-infection. Cells were infected at an MOI of 0.5.
Antibody binding was detected with AlexaFluor 488 anti-mouse IgG secondary
antibody (green) and nuclei were stained with DAPI (blue). Overlay images are
shown. (B) GPCMV that was treated (left panel) or not treated (right panel) with
UV. Three different MOIs are shown. Cells were ﬁxed and stained at 24 h post-
infection with the anti-gB antibody as described above.Results
Assay and primary cell development for the study of GPCMV
The gold standard for titering GPCMV is the TCID50 assay and
the plaque assay. These methods, however tried and true, involve
lengthy read-outs and are cell-culture reagent intensive. We
sought to develop an alternative immunoﬂuorescence assay
(IFA), similar to that utilized for HCMV. We found that an anti-
GPCMV glycoprotein B monoclonal antibody (29-29) produced
strong, speciﬁc anti-viral staining. Although HCMV gB is charac-
terized as a late protein, we have been able to detect robust
expression in infected cells at 24 hpi by Western blot (data not
shown) and by immunoﬂuorescence (Fig. 1A)(Britt and Harrison,
1994; Spaete et al., 1988). Although we observed greater staining
at 48 hpi, the percent of cells infected at 24 hpi corresponded to
the input inoculum as determined by TCID50. Moreover, we could
detect spread at 48 hpi, as deﬁned by 42 contiguous cells
infected, but not at 24 hpi, suggesting that we are visualizing
primary infection at 24 hpi (Fig. 1A). When the viral inoculum was
UV-treated prior to infection, we did not detect anti-gB staining,
indicating that the cytoplasmic staining is the result of replicated
virus (Fig. 1B). IFA was additionally used as readout for a GPCMV
neutralization assay.
Studies concerning GPCMV cell entry have been hampered by
the lack of available guinea pig primary cells. There are only two
commercially available guinea pig cell lines and we deemed both
unsuitable for this study (guinea pig lung ﬁbroblast cell line, ATCC
CCL-158, gives rise to cultures with heterogeneous morphology,
and guinea pig epithelial cell line, ATCC CCL-242, is non-
permissive for GPCMV). In an effort to generate cells that are
relevant, characterized, and permissive to GPCMV infection, we
isolated ﬁbroblasts from 40-day old guinea pig embryos and
endothelial cells from adult guinea pig lungs and aortas and sorted
both tissues with the endothelial cell marker CD31/PECAM-1
(Conner, 2001; Kobayashi et al., 2005). To characterize these cells,
we generated a panel of ﬁbroblast- and endothelial-speciﬁc
markers for relative qRT-PCR (Supplemental Table 1). We based
this panel on known markers for human and mouse ﬁbroblast and
endothelial cells and the availability of the guinea pig genome
sequence (Garlanda and Dejana, 1997; Pilling et al., 2009). The
qRT-PCR analysis demonstrated a clear enrichment of each cell-
speciﬁc marker on the corresponding cell type (Supplemental
Fig. 1). These primary cells were permissive to GPCMV as detected
by cytopathic effect, IFA staining, and qPCR for the presence of a
viral tegument gene (GP83) (Fig. 1A and data not shown). Due to
the relevant nature of these cells, we chose to move forward with
only primary cells in these studies.
Re-evaluation of the genomic landscape of the 1.6 kb locus
The glycoprotein complexes involved in the cellular entry of
HCMV have been well characterized both biochemically and cell
biologically. In contrast, the mechanisms regarding the entry of
GPCMV are relatively unknown. To better understand the genomic
landscape of the so-called “tropism” locus containing GP129 and
GP131, we generated GPCMV cDNA from a pool of poly(A) RNA
puriﬁed from GPCMV-infected cells and ampliﬁed the entire locus
using primers based on the published genomic sequenceencompassing the entire 1.6 kb region (Nozawa et al., 2008). The
PCR reaction yielded three products that were individually cloned
and sequenced. Two of the three products were incompletely
spliced (i.e. contained introns in GP129 and GP131) and we moved
forward with the cDNA that was completely spliced. As we did not
follow up on the incompletely spliced products, we do not know if
these products play a role in replication. Consistent with previous
reports, we found that the GP129 and GP131 genes are found on
the negative strand of the viral DNA genome, and that both genes
are spliced, contain signal sequences, and lack transmembrane
domains (Fig. 2A) (Kanai et al., 2011; Nozawa et al., 2008; Yamada
et al., 2009). Both GP129 and GP131 sequences are identical to
those published (Kanai et al., 2011; Nozawa et al., 2008).
Our analyses of these protein sequences revealed that GP129
and GP131 contain putative CC-type chemokine and CX-type
chemokine motifs, respectively (Fig. 2A). Chemokine motifs are
Fig. 2. Annotation of the GP129-133 locus. (A) Schematic of the GPCMV 129-133 locus with ORF designations and splice junctions shown. The locus is expressed from the
Crick strand as a single mRNA. (B) Amino acid sequences of GP129, GP131, and GP133. Residues highlighted in red indicate cysteine residues that form putative chemokine
folds and residues highlighted in green indicate predicted α-helicies for GP133. (C) Topological comparison of the predicted α-helical secondary structures in CCMV UL131A
(purple) and GP133 (green). The relevant portion of the primary sequence is shown.
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RCMV, CCMV and HCMV (Hahn et al., 2004). HCMV UL128 gene
encodes a protein with a CC-type chemokine domain (Hahn et al.,
2004). More recently, it was shown that soluble recombinant
pUL128 was able to down-regulate host cell chemokine receptors
and was sufﬁcient to block migration of monocytes (Straschewski
et al., 2011). GP129 has overall 48% amino acid similarity to UL128,
and contains a CC-type motif at similar position in the amino acid
sequence. Additionally, HCMV UL130 has been shown to be
important for the infection of leukocytes (Hahn et al., 2004) and
more recently has been described as containing a putative
N-terminal CX-type chemokine motif (Malkowska et al., 2013;
Wyrwicz and Rychlewski, 2007). The CX-type (also called C-type)
motif involves only one cysteine bridge (instead of two) in a given
chemokine fold. GP131 has overall 36% amino acid similarity
to UL130, and contains a single putative CX-type motif at the
N-terminus.
We conﬁrmed the expression of a third gene, located 5′ of
GP129 and GP131 on the cDNA, named GP133. This gene encoding
a 127 amino acid protein was predicted by the initial annotation
of this locus reported previously (Nozawa et al., 2008). GP133 is
co-cistronic with GP129 and GP131, and its protein product is
predicted to be largely alpha-helical in structure with three
distinct alpha-helical domains, in which chimpanzee CMV (CCMV)
UL131A contains the highest domain homology (32% similarity;
Fig. 2B and C). Although the overall percentage amino acid
similarity between GP133 and HCMV UL131A is low (29% similar-
ity, 20% identity), we predict that GP133 is the homolog of UL131Adue to the conserved protein domain architecture and syntenic
position in the genome (Fig. 2C).
Characterization of GPCMV gH, gL, GP129, GP131, and GP133 proteins
To biochemically characterize the gH, gL, GP129, GP131, and
GP133 proteins, we co-expressed all ﬁve proteins with C-terminal
His tags in the baculovirus system. The transmembrane domain of
gH was deleted to ensure soluble expression. Co-expressed pro-
teins were puriﬁed over nickel resin and analyzed by Coomassie
staining (data not shown) and Western blot (Fig. 3A). Bands for
each of the ﬁve proteins were observed at the predicted molecular
weights, as shown by the rabbit polyclonal anti-peptide antibodies
(Fig. 3A). When we probed blots with a mouse anti-his antibody
we were able to distinguish among the gH, GP131 and GP133
proteins, as these bands ran at the predicted molecular weights
(Fig. 3A). However, gL and GP129 proteins co-migrate in SDS-PAGE
and could not be distinguished using the anti-his antibody
(Fig. 3A). Despite attempts to express these proteins in equal
ratios, the anti-his Western blots show greater signal for gL and/or
GP129, than gH, GP131, and GP133. It is possible that gL and/or
GP129 are expressed in greater amounts or that the anti-his
antibody recognizes gL and GP129 better due to accessibility. In
any case, we cannot infer stoichiometry from these results. We
also performed Western blot analysis on GPCMV-infected ﬁbro-
blast cells (Fig. 3B). During infection, each component appeared to
have slower migration, possibly due to modiﬁcation such as
glycosylation (Fig. 3B).
Fig. 3. Characterization of gH, gL, GP129, GP131, and GP133 and evidence of a
pentameric complex. A–C, samples were run on a 4–12% gradient bis-Tris SDS-PAGE
gel. (A) Co-expression of the soluble GPCMV gH/gL/GP129/GP131/GP133 in bacu-
lovirus. Western blot analysis using a mouse anti-his antibody and rabbit poly-
clonal antibodies against each protein and are shown. (B) Expression of GPCMV gH,
gL, GP129, GP131, GP133 proteins in GPCMV-infected ﬁbroblast cells. Comparison
with uninfected cell lysates (U) is shown to the left of the infected cell lysates (I).
Proteins were analyzed by immunoblotting with rabbit anti-peptide antibodies
directed against each protein. (C) Co-immunoprecipations of the baculovirus-
derived GPCMV gH, gL, GP129, GP131, GP133 proteins were performed with an
anti-GPCMV gH antibody (mAb 394) or with a species control antibody against
GPCMV gB (29-29). Immunoprecipitations were followed by SDS-PAGE/Western
blot using rabbit polyclonal antibodies against each protein. (D) Co-immunopreci-
pations of the baculovirus-derived GPCMV gH, gL, GP129, GP131, and GP133
proteins were performed with rabbit anti-GP129, -GP131 and -GP133 peptide
antibodies and detected with a mouse anti-his antibody. Samples were run on a
10% bis-Tris SDS-PAGE gel. Panels are different ﬁlm exposures of the same Western.
An in-house irrelevant rabbit peptide antibody was used as a negative control.
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To determine whether these proteins form a pentameric com-
plex analogous to the HCMV gH/gL/UL128/UL130/UL131 complex,
we performed immunoprecipitations from baculovirus-expressedgH, gL, GP129, GP131 and GP133 proteins. First, we immunopre-
cipitated gH with a mouse monoclonal anti-GPCMV gH antibody
(394, generated in-house) or a mouse monoclonal anti-GPCMV gB
antibody (29-29) as a species control (Fig. 3C). As expected, gH
protein was immunoprecipitated by the anti-GPCMV gH antibody,
with relatively minimal gH protein in the negative control lane
(Fig. 3C). We also found that gH protein co-immunoprecipitated
with gL protein, suggesting formation of a gH/gL heterodimer
complex, analogous to that found in HCMV. In addition, gH protein
co-immunoprecipitated GP129, GP131 and GP133 proteins,
whereas the negative control antibody did not (Fig. 3C).
In addition, we performed the converse experiment by immu-
noprecipitating the GP129, GP131 and GP133 proteins with the
rabbit polyclonal anti-peptide antibodies (anti-GP129, anti-GP131
or anti-GP133). For this experiment, proteins were detected with a
mouse anti-his antibody (each protein is his-tagged) instead of the
rabbit antibodies due to cross-reactivity of antibody heavy and
light chains with the rabbit antibodies used for immunoprecipita-
tion. Furthermore, the anti-gH monoclonal could not be used for
Western analysis due to recognition of a non-linear epitope (data
not shown). Anti-GP129, anti-GP131 and anti-GP133 antibodies
each co-immunoprecipitated gH, GP131 and GP133, whereas a
rabbit irrelevant control antibody did not (Fig. 3D). As expected,
the anti-GP131 and anti-GP133 immunoprecipitations appeared to
pull down more GP131 protein and GP133 protein, respectively
(Fig. 3D). Since gL and GP129 share a similar molecular weight (see
Fig. 3A), we could not determine which proteins were speciﬁcally
co-precipitated. Moreover, we could not use the rabbit antibodies
to distinguish between gL and GP129, due to co-migration with
rabbit antibody light chain. There is a faint band of the same
molecular weight as gL/GP129/light chain in the negative control
lane; however, this band is present at drastically reduced levels as
compared with the anti-GP129, -131, and -133 lanes. Demonstra-
tion that gH co-immunoprecipitated gL, GP129, GP131, and GP133,
and in addition, GP129, GP131, and GP133 co-immunoprecipitated
gH, GP131 and GP133 (and likely gL and/or GP129) strongly
suggests complex formation among the components. Furthermore,
these results do not rule out sub-complex formation among the
components. We were unable to detect the interaction between
GP129/GP131/GP133 and gH/gL from infected cells, possibly due to
reduced protein levels of GP129/GP131/GP133 during infection
(data not shown).
Isolation of a GP129-133 deletion mutant
To understand the function of the gH/gL/GP129/GP131/GP133
complex in GPCMV, we selected for the strain carrying the GP129-
133 deletion locus by limiting dilution of the ATCC strain, 22122. In
contrast to previously published reports, we isolated the deletion
variant in primary guinea pig ﬁbroblast and endothelial cells
(Nozawa et al., 2008). The deletion strain was isolated from single
plaques on either cell type. This is in contrast to HCMV in which
the deletion of this locus occurs only after serial passaging in
ﬁbroblast cells but not endothelial cells. Using the P1/P2 primers
described previously that ﬂank the GP129-133 locus, we ampliﬁed
both the 1.6 kb band (wildtype GP129-133 locus) and the 0.4 kb
band (deletion of the GP129-133 locus) from virus grown on both
cell types and selected for plaques by PCR that only ampliﬁed a
0.4 kb band (Fig. 4A and data not shown)(Nozawa et al., 2008). To
conﬁrm that we had isolated a deletion, we compared pelleted
virus from the parent 22122 strain and the strain isolated via
limiting dilution (referred to in Fig. 4A as ΔGP129-133) by
SDS-PAGE and Western blot analysis. While an anti-gB antibody
was able to react with both the parent 22122 strain and the
ΔGP129-133 deletion strain, only the 22122 strain reacted with
the anti-GP133 antibody corresponding to a single 15-kD band of
Fig. 4. Isolation and validation of ΔGP129-133 deletion strains. (A) ΔGP129-133 was isolated from primary guinea pig ﬁbroblast cells. PCR reactions were performed with P1
and P2 primers (see panel C). MW¼molecular weight, NTC¼no template control. (B) Pelleted virus from strain 22122 and the ΔGP129-133 variant was analyzed by Western
blot using a mouse anti-gB antibody (29-29) and rabbit anti-GP133 antibody. (C) Boundaries of the deletion clone are shown. P1/P2 primers amplify the region spanning the
1.6 kb region, P5/P6 amplify the wildtype locus by qPCR, and P7/P8 amplify the deletion locus by qPCR. The red bars denote the qPCR probes for the wildtype locus (probe F)
and the deletion locus (probe D).
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also conﬁrmed by immunohistochemistry by staining infected gefs
using anti-GPCMV gL and anti-GP133 rabbit polyclonal antibodies
(Supplemental Fig. 2).
We sequenced the deletion strains isolated on both ﬁbroblasts
and endothelial cells and found these sequence deletion bound-
aries to be consistent with previous reports (Fig. 4C) (Nozawa
et al., 2008; Yamada et al., 2009). Similar to published reports, we
attempted to make a pure “wildtype” strain (i.e. only contains the
1.6 kb locus) in vitro by limiting dilution followed by plaque
puriﬁcation (Nozawa et al., 2008). We were able to identify several
strains that contained only the 1.6 kb locus. However, these
puriﬁed wildtype strains consistently gave rise to a mixed strain
(data not shown). We also attempted to generate a wildtype strain
by serial passaging in vivo. Despite 13 serial passages in vivo, the
GP129-133 deletion strain could be detected in the salivary gland
(Supplementary Fig. 3). These in vitro and in vivo ﬁndings strongly
suggest genetic instability at this locus, similar to HCMV.
Characterization of the GP129-133 deletion mutant
In HCMV, the UL128-131A deletion strain shows an entry defect
in macrophages, endothelial cells, and epithelial cells (Sinzger
et al., 2008). To examine whether the GP129-133 deletion strain
has a defect in cellular entry, we infected primary endothelial cells
with equal numbers of viral genomes (as determined by qPCR) ofwildtype and deletion virions. Endothelial cells were infected with
4108 genomes per 2104 cells and ﬁxed at 24 hpi and stained
with the monoclonal anti-GPCMV gB antibody (29-29). We found
that the deletion strain entered endothelial cells 90% less efﬁ-
ciently than wildtype (Fig. 5A). To determine whether this entry
defect was limited to endothelial cells, we performed the same
experiment in ﬁbroblast cells. We found that the deletion strain
had an entry defect in ﬁbroblast cells to a similar extent as
endothelial cells (Fig. 5A). In contrast, the HCMV UL128-131A
complex is critical for endothelial entry but dispensable for
ﬁbroblast entry. This difference may be due to the functions of
the viral glycoproteins or differences between human and guinea
pig ﬁbroblast cells. In addition, we found that guinea pig hyper-
immune globulin (GP-HIG) neutralized viral entry to an equivalent
extent on ﬁbroblasts and endothelial cells (Fig. 5B). This is in
contrast to human hyperimmune globulin, which is 100-fold more
neutralizing at blocking viral entry into endothelial cells than
ﬁbroblasts, due to antibodies that speciﬁcally neutralize the HCMV
UL128-131A complex (Fouts et al., 2012). Taken together, these
data suggest that similar to HCMV 128-131A, the GP129-133 locus
plays a role in viral entry and that this role can be extended to
ﬁbroblast cells.
To assess if the GP129-133 locus is required for cell-to-cell
spread, we compared the ability of the GP129-133 deletion and
22122 strain to spread in ﬁbroblasts. We infected gefs with
wildtype at a MOI of 0.1 or with an equivalent number of genomes
Fig. 5. Evaluation of the ΔGP129-133 virus and guinea pig hyperimmune globulin (GP-HIG) on primary-guinea pig endothelial and ﬁbroblast cells. (A) Comparison of
infection of the 22122 strain and the ΔGP129-133 virus. Viral inoculums were equalized by viral genome copy number and stained for anti-GPCMV gB at 24 hpi.
(B) Neutralization of the 22122 strain by GP-HIG on both cells types with EC50s shown.
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immunoﬂuorescence using an anti-gB antibody (29-29) over the
course of 7 days. We found that the GP129-133 deletion strain was
initially delayed as compared with wildtype (Fig. 6A, 48–96 hpi).
However by day 7, the GP129-133 deletion strain was able to
spread to a similar percentage of cells as the 22122 strain (Fig. 6A).
Using primer/probe sets speciﬁc for the GP129-133 locus (refer to
Fig. 4C for primer locations), we determined that the growth was
due to the GP129-133 deletion strain rather than contamination
from wildtype (Fig. 6B). Thus, the deletion strain is able to spread
cell-to-cell with similar kinetics to wildtype (i.e. similar growth
curve slopes), but that the growth lag is likely due to an initial
defect in entry.
To assess if the GP129-133 locus is required for in vivo spread,
we compared the ability of the GP129-133 deletion, 22122 strain,
and IVP8 (a virulent strain passaged eight times in vivo) to spread
to the salivary gland. To this end, we infected male Hartley guinea
pigs (5 animals per group) subcutaneously with each virus stock at
1105 PFU and measured the viral copy number via GP83
(tegument protein) in the salivary glands at day 21 post-
infection (Fig. 6C, left panel). Of note, 1105 PFU of the GP129-
133 deletion strain contains approximately 10-fold as many
genomes as wildtype. As expected, we could detect both the
22122 strain (ave. copy number of 1.4105 genomes/salivary
gland (SG)) and IVP8 (ave. copy number of 1.3106 genomes/
SG) in the salivary gland. However, the deletion strain failed to
spread to the salivary gland, despite an inoculum of 1105 PFU. As
expected, the 1.6 kb (wildtype) locus could be ampliﬁed (primers
P5/P6) from both the 22122- (ave. copy number of 3.6106
genomes/SG) and IVP8-infected samples (ave. copy number of
2.6107 genomes/SG; Fig. 6C, center panel). Despite the failure of
the deletion strain to spread in vivo, we could still detect the
deletion virus (primers P7/P8) in salivary glands infected with
either the 22122 strain (ave. copy number of 2.8105 genomes/SG)
or IVP8 (ave. copy number of 5.2104 genomes/SG) (Fig. 6C, right
panel). Since the deletion strain fails to spread to the salivary
gland, this suggests that the wildtype strain can give rise to the
deletion strain in vivo, further suggesting genomic instability at
this locus.Discussion
GPCMV is the closest non-primate relative to HCMV, and bears
stronger phylogenetic similarity to primate CMVs than to rodent
CMVs (Schleiss et al., 2008). In contrast to the CMVs of other small
mammals, GPCMV crosses the placenta, infects the fetus in utero,
and produces disease in newborn guinea pigs (Grifﬁth and
Aquino-de Jesus, 1991; Schleiss, 2006). The structural similarities
between the human and guinea pig placentas, coupled with the
relatively long guinea pig gestational period, has made the guinea
pig a highly useful model for the study of congenital CMV infection
(Schleiss, 2006). Considering the signiﬁcance of the guinea pig
model as the only bona ﬁde small animal CMV congenital infection
model, we sought to accomplish the following objectives: (1)
introduce a fast, alternative assay to titer viral stocks, (2) introduce
the use of guinea pig primary cells for in vitro culture, and (3)
characterize the role of the gH/gL/GP129/GP131/GP133 complex in
GPCMV entry and spread. Our aim is that these contributions
beneﬁt the general study of congenital CMV in addition to the
advancement of the guinea pig CMV model.
HCMV entry is facilitated by several entry glycoprotein com-
plexes, with gH/gL/UL128/UL130/UL131A required for viral entry
into epithelial cells, endothelial cells, and macrophages, but not
ﬁbroblast cells (Hahn et al., 2004; Wang and Shenk, 2005a,
2005b). The neutralizing component of human hyperimmune
globulin and the most potent human anti-CMV antibodies
described to date are directed against the gH/gL/UL128/UL130/
UL131A complex (Fouts et al., 2012; Genini et al., 2011; Macagno
et al., 2010; Wang et al., 2011). Despite the biological signiﬁcance
of the HCMV gH/gL/UL128/UL130/UL131A complex, there is little
known about an analogous complex in GPCMV.
Here, we have identiﬁed the GPCMV homolog of UL131A, called
GP133, and shown that it can associate with gH, gL, GP129 and
GP131. Although the amino acid similarity between HCMV UL131A
and GP133 is low (29%), we conclude that GP133 is the UL131A
homolog from the following lines of evidence: (1) both are
predicted to contain three conserved alpha-helical domains, in
which chimp CMV UL131A contains the highest domain homology
and are 32% similar (Fig. 2C), (2) both genes are located in syntenic
Fig. 6. Comparison of the 22122 strain and the ΔGP129-133 strain in cell-to-cell spread both in vitro and in vivo. (A) In vitro spread assay comparing the growth of the 22122
strain (black) and ΔGP129-133 strain (red) over 7 days. Gefs were infected with wildtype at a MOI of 0.1 or with an equivalent number of genomes of the ΔGP129-133 strain
and stained with an anti-GPCMV gB antibody. (B) Quantitative PCR of the released virus at d7 post-infection targeting GP83, the wildtype (P5/P6) locus, and the deletion
(P7/P8) locus. (C) Quantitative PCR of virus in salivary glands from guinea pigs infected with 22122, IVP8, or ΔGP129-133 virus targeting GP83, the GP129-133 wildtype locus
(P5/P6) and the GP129-133 deletion (P7/P8) locus. Error bars indicate standard error of the mean.
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are co-cistronic with GP129 and GP131 or UL128 and UL130,
respectively, and (4) both GP133 and UL131A proteins form a
biochemical complex with gH, gL, and GP129/UL128, and GP131/
UL130 (Fig. 3C and D). We recognize the caveats associated with
concluding complex formation from baculovirus-expressed pro-
teins, but we were unable to detect the interaction between
GP129/GP131/GP133 and gH/gL from infected cells. We believe
that this reﬂects our inability to detect relatively small amounts of
GP129/GP131/GP133 protein as compared with gH/gL, as opposed
to a lack of an interaction. Our data taken together with demon-
stration of an analogous complex from HCMV suggests that
GPCMV gH/gL/GP129/GP131/GP133 forms a pentamer complex,
but does not rule out the formation of sub-complexes.
We have demonstrated that the GPCMV gH/gL/GP129/GP131/
GP133 complex is functionally and structurally analogous to the
HCMV gH/gL/UL128/UL130/UL131A complex. First, similar to
HCMV UL128/UL130/UL131A, we have shown that GPCMV
GP129/GP131/GP133 can form a pentamer complex with gH/gL
(Fig. 3). Both the GPCMV and the HCMV pentamer complexes
contain components with putative chemokine domains (GP129/
UL128, GP131/UL130) and a component with a tri-alpha-helical
repeat structure (GP133/UL131A). Second, both of these complexes
are critical for efﬁcient viral entry into cells. In the case of GPCMV,
this complex plays a role in viral entry into both endothelial and
ﬁbroblast cells, whereas in HCMV, the complex is dispensable for
entry into ﬁbroblasts. This difference is likely due to the functions
of the viral glycoproteins but may be due to differences betweenhuman and guinea pig ﬁbroblast cells. We acknowledge the
limitations of our conclusions from two cell types; however,
generating and characterizing additional primary guinea pig cells
has proven to be technically challenging. Consistent with GP129-
133 proteins playing a role in viral entry, we found that the GP129-
133 deletion strain failed to spread in vivo (Fig. 6). Third, both
HCMV and GPCMV exhibit genetic instability at this locus. Lab-
adapted HCMV strains that have been serially passaged in ﬁbro-
blasts are functional deletions of the UL128-131A locus (Wang and
Shenk, 2005a, 2005b). Similarly in GPCMV, the GP129-133 dele-
tion strain is spontaneously generated from wildtype and perpe-
tuated both in vitro and in vivo passage (Figs. 4, 6 and
Supplementary Fig. 3). This study provides evidence for a GPCMV
gH/gL/GP129/GP131/GP133 complex and suggests that GPCMV
uses entry mechanisms analogous to that of HCMV.
Analysis of the GP129-133 deletion strain suggests that the
129-133 locus, despite its role in entry, is dispensable for in vitro
spread, but is required for in vivo spread (Fig. 6). The GP129-133
deletion strain demonstrated an initial lag in growth, but was able
to reach wildtype levels of virus after 7 days (Fig. 6A and B). This
likely reﬂects an extracellular entry defect, but not a subsequent
defect in cell-to-cell spread, suggesting a gH/gL/GP129-133-inde-
pendent mechanism for spreading between cells. In vivo, the
Δ129-133 strain failed to spread to the salivary gland (Fig. 6C).
To reconcile the difference between the in vitro and in vivo results,
we propose that the null strain fails to establish infection in the
salivary gland due to the requirement for at least two rounds of
extracellular entry: one at the injection site, and one at the salivary
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infection in the salivary gland. However, once established in the
salivary gland or perhaps at an unspeciﬁed intermediate site, the
wildtype strain gives rise to the GP129-133 deletion strain in situ,
suggesting genetic instability at this locus. This instability may
arise due to the gH/gL/GP129-133 complex not being required for
spread between cells. This ﬁnding is consistent with our observa-
tion that plaque-puriﬁed wildtype strains (1.6 kb product) regen-
erate the deletion strain in vitro, making it technically challenging
to passage a true wildtype strain. Nozawa et al. (2008) reported
the isolation of a true wildtype strain (termed GPCMV/full) after
passaging in GPL cells, or a combination of in vivo followed by
in vitro passage (Nozawa et al., 2008). One possible difference
between these results is that we have used highly characterized
primary guinea pig cells for our studies, which may be more
relevant to GPCMV biology. Even after 13 serial passages in vivo,
we could still detect the deletion of the GP129-133 locus, indicat-
ing genetic instability at the GP129-133 locus in vivo and suggest-
ing a growth advantage of the deletion mutant (Supplemental
Fig. 3).
We describe in this paper a sensitive, quick method for the
detection of GPCMV infection and titering of viral stocks. Despite
gB being characterized as a viral late gene, we are able to detect
robust gB straining at 24 hpi and found that quantitation of
infected cells by anti-gB IFA was equivalent to that determined
by TCID50. As a result, we were able to reliably use the IFA for
titering and adapted this to develop a viral microneutralization
assay (Fig. 1 and Supplemental Fig. 4), similar to that currently
used for HCMV.
GPCMV is unique in its ability to cross the placenta and cause
fetal infection. The guinea pig model has been useful in studying
the mechanisms of maternal-fetal transmission (e.g. cell types,
route of infection, etc.), in highlighting the importance of pre-
conception immunity, and in the development of vaccines. How-
ever, our study suggests that the guinea pig model has limited
utility to study vaccines and therapeutics that target the HCMV
UL128-131A complex, due to the non-analogous roles in entry.
There has been a recent focus on the role of HCMV UL128-131A in
pre-conception immunity and if antibodies against this complex
correlate with fetal protection (Gerna et al., 2008; Wang et al.,
2011). Despite these limitations, the guinea pig model can be used
to address the protective role of antibodies against other viral
entry proteins, such as gB and gH. Ultimately, we hope that this
study serves as a technological step forward in the advancement of
the guinea pig model, while at the same time deepening the
biological understanding of GPCMV.Materials and methods
Cells, viruses, and animals. Transformed guinea pig lung ﬁbro-
blasts (GPL, ATCC CCL-158) were cultured in F-12 medium supple-
mented with 10% fetal bovine serum (FBS). GPLs were initially
used to propagate GPCMV as described (Britt and Harrison,
1994). After the generation and extensive characterization of our
in-house guinea pig primary ﬁbroblasts, we preferentially used
these cells in lieu of the GPLs. Guinea pig embryonic ﬁbroblasts
(gefs) were generated from 40-day embryos of Hartley guinea pig
purchased from Elm Hill Breeding Labs (Tynsboro, MA and
Chelmsford, MA) (Conner, 2001). Gefs were grown in Dulbecco's
modiﬁed eagle medium (DMEM) containing 10% FBS, penicillin,
and streptomycin. Primary lung and aorta endothelial cells were
isolated from adult male Hartley guinea pigs, using a protocol
adapted from the literature (Sobczak et al., 2010). Primary
endothelial cells were sorted with human anti-CD31/PECAM-1
(R&D Systems) and grown in Endothelial Cell Basal Medium-2(Clonetics) on ﬂasks coated with 1% gelatin. Passaging of the
primary endothelial and ﬁbroblast primary cells were limited to
up to 6, and 14 passages, respectively.
We created a panel of guinea pig ﬁbroblast-speciﬁc (CD90/
Thy1, tenascin) and guinea pig endothelial-speciﬁc (platelet/
endothelial cell adhesion molecule, PCAM-1/CD31, endothelial
speciﬁc molecule-1, Nos3, VEGF-2, MUC18) markers to character-
ize these primary cells by quantitative RT-PCR. We based this
panel on published markers for human and mouse ﬁbroblast and
endothelial cells and the availability of genomic guinea pig
sequences (Garlanda and Dejana, 1997; Pilling et al., 2009;
Kobayashi et al., 2005). RNA was isolated from guinea pig ﬁbro-
blast and endothelial cells using the RNeasy Mini Kit (Qiagen) and
reverse transcriptase reactions were performed using the High
Capacity cDNA reverse transcriptase Kit (Applied Biosystems).
Guinea pig speciﬁc qPCR primers and probes were designed using
the Primer Express Software v3.0 (Applied Biosystems, Supple-
mental Table 1) with the predicted guinea pig (Cavia porcellus)
sequences obtained from NCBI via the Guinea Pig Genome Project
at the Broad Institute (Cambridge, MA). All Ct values are normal-
ized to guinea pig actin and the normalized fold differences were
graphed (Prism, GraphPad Software). qPCR reactions were run in
triplicate and error bars indicate standard error of the mean.
GPCMV (strain 22122, American Type Culture Collection) was
propagated on gefs. To make viral stocks, cells were infected with
the GPCMV strain 22122, at an MOI of 0.01 and harvested between
7 and 9 days post-infection, when ~50% of the cells were detached
from the plate. Cells were scraped, and the viral supernatant was
spun down to remove cellular debris. Virus was stored in frozen
aliquots at −80 1C at 1:1 in 0.2 M sucrose phosphate buffer. To
determine the titer of a given stock, an aliquot was thawed and
titered. A TCID50 assay was initially employed to titer stocks.
However this titering technique was augmented by the more
facile immunoﬂuoresence assay (IFA) using the mouse monoclonal
antibody raised against GPCMV gB (29-29, gift from Bill Britt at the
University of Alabama) (Britt and Harrison, 1994). The cells were
ﬁxed in ethanol at 24 hpi, blocked with PBS containing 2% bovine
serum albumin (BSA), and stained with anti-gB (29-29) at 2 mg/mL,
anti-mouse AlexaFluor 488 and DAPI stain (Invitrogen). The cells
were imaged and scored using the Image Express Micro and
MetaXpress software (Molecular Devices). IFA at 24 hpi gave
comparable titers to TCID50 at 14 days post-infection. Viral stocks
typically had titers of 105–106 PFU/ml on ﬁbroblast and
endothelial cells.
For Western blotting, virus was partially puriﬁed and pelleted
from the supernatant of infected cells. The medium was layered
over a sorbitol cushion (20% D-sorbitol in PBS) and virus was
pelleted by ultracentrifugation (22,000 rpm, 90 min, SW28 Beck-
man rotor). Viral pellets were resuspended in lysis buffer (50 mM
Tris, 150 mM NaCl, 0.1% SDS, 1% NP-40, Complete, Mini protease
inhibitor cocktail tablet from Roche) and subsequently prepared
for SDS/PAGE-Western blot analysis.
In vitro generated viral stocks were passaged in vivo by the
following method: adult male Hartley guinea pigs (Elm Hill
Breeding Labs, Tynsboro and Chelmsford, MA) were infected
subcutaneously with 105 PFU of tissue culture-derived virus stock.
After 21 days of infection, the salivary gland was removed,
homogenized, sonicated, clariﬁed and used for re-infection as
previously described (Hartley et al., 1957). After each passage,
virus was stored in frozen aliquots at −80 1C at 1:1 in 0.2 M
sucrose phosphate buffer at 105 PFU/ml. Before their use in the
study, all animals were tested for GPCMV antibodies by neutrali-
zation assay and only GPCMV-free animals were used. All guinea
pigs were housed under conditions approved by the American
Association of Accreditations of Laboratory Animal Care
Committee.
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duced by infecting 10 GPCMV-free adult Hartley male guinea pigs
subcutaneously with tissue-culture derived GPCMV at 106 PFU/
animal (1 ml total volume). Antibody responses were boosted by
two subsequent injections at 3-week intervals with 106 PFU/
animal. Prior to each injection, serum was collected and tested
for neutralization with GPCMV. Terminal bleeds from infected
animals were taken at 9-weeks post the initial injection, pooled,
and afﬁnity puriﬁed for IgG. In a separate experiment, non-
immune negative control serumwas generated from 10 uninfected
Hartley male guinea pigs and afﬁnity puriﬁed for IgG. The afﬁnity
puriﬁed GP-HIG and non-immune IgG was tested for neutraliza-
tion activity on primary guinea pig ﬁbroblast and endothelial cells.
Neutralization assays. GPCMV neutralization assays were based
on assays from the HCMV literature (Abai et al., 2007). Brieﬂy,
guinea pig hyperimmune globulin (GP-HIG) or non-immune IgG
was serially diluted in complete DMEM and mixed with virus
diluted in DMEM such that the ﬁnal virus concentration resulted
in approximately one infectious virus per cell (MOI¼1) when
mixed with media. Antibody and virus were mixed and incubated
at 37 1C for 1 h prior to incubation for 24 h on a conﬂuent
monolayer of cells. At 24 hpi, cells were ﬁxed and stained with
the anti-GPCMV gB antibody (29-29) as described above. Data
from duplicate wells containing a given antibody concentration
were averaged and compared with infection in the absence
of antibody, which was set to 100%. Data were graphed using
Prism (GraphPad Software; La Jolla, CA), and EC50 values were
calculated from best-ﬁt curves using Prism EC50-curve ﬁtting
algorithm.
Peptide antibodies. Rabbit polyclonal antibodies were generated to
GPCMV gH, gL, GP129, GP131 and GP133 for biochemical analyses
and immunohistochemistry. The following rabbit polyclonal antibo-
dies were generated: gH (raised against SPQELYNWAPHVSSAGLTM-
QEMFTPCSGSGRRDYTE), gL (raised against CVRRILYQASLSGPHRDA-
PIHNYLNRDLS), GP129 (raised against CSSKDRRVQHSTTSND), GP131
(raised against CYYPSTPIPKSFVKHV), and GP133 (raised against
CENQLAHYILKTIVLTHHRR) (YenZym Antibodies, South San Francisco).
Antibodies were afﬁnity-puriﬁed on peptide.
Immunohistochemistry. Guinea pig ﬁbroblast cells were infected
at an MOI of 1 for 24 h and cell pellets were immersed for 24 h in
neutral-buffered formalin at ambient temperature, parafﬁn-
embedded, then sectioned at 4 μm and mounted on glass slides.
Slides were stained with anti-GP gL and anti-GP133 antibodies on
a Ventana Discovery XT Autostainer, with Ventana CC1 standard
digestion and Ventana Rabbit OmniMap DAB detection. Images
were captured on a Nikon E800 microscope equipped with a Leica
DFC500 camera and Leica Application Suite software (v 3.6.0).
Digital magniﬁcation and image compression was performed in
Adobe Photoshop CS3 (v 10.0.1).
Cloning, sequencing, and annotation. GPCMV cDNA was gener-
ated from a pool of poly(A) RNA puriﬁed from GPCMV-infected
cells, and the entire locus was ampliﬁed using primers encom-
passing the entire 1.6 kb region (129rev CCTGTATCGGCGAAA-
GACA), 133 for (ATGTTTTGGCGTCTTGTATATGTCTA) based on
genomic sequence from the literature (Nozawa et al., 2008). The
PCR reaction yielded three products that were individually cloned
into the TOPO vector (Invitrogen) and sequenced. The PCR product
did not contain sequences corresponding to gp130 and gp134. The
locus is expressed from the Crick (negative) strand as a single
mRNA. Sequencing and comparison of the cDNA and genomic DNA
sequences conﬁrmed that GP129 and GP131 are spliced and GP133
is unspliced. Secondary structure predictions were made using
Protein Structure Prediction (PELE) on Biology Workbench
(Subramaniam, 1998). The chimpanzee CMV (CCMV, Panine her-
pesvirus 2) UL131A sequence (accession no. AF480884) was used
in the alignment in Fig. 2C.Baculovirus production of GPCMV glycoproteins. Recombinant
plasmids made from cDNA clones were used to subclone GPCMV
gH, gL, GP129, GP131, and GP133 containing C-terminal His tags.
For expression in baculovirus of gH, the transmembrane domain
was eliminated to maximize secretion into the media. Native signal
sequences were removed and replaced with the insect signal
sequence. In brief, Spodoptera frugiperda (Sf9) and Trichloplusia ni
(Tni) cells were obtained from Expression Systems LLC. Cells were
maintained in ESF921 complete insect media in shake ﬂasks. For
generation of recombinant baculovirus, Tni cells were transfected
with plasmid DNA using Baculogold cotransfection reagent (BD
Biosciences). Stocks of recombinant baculovirus expressing GPCMV
glycoproteins were passaged 3 times in Sf9 cells and stored in 2%
HIFBS. For protein expression, Tni cells in shake ﬂasks or wave
bioreactors were infected at a density of 2106 cells/ml and co-
infected at an MOI of 1 in equal ratios. Cells were incubated at 37 1C
and supernatant was harvested at 72 h post infection. Protein was
then puriﬁed over nickel resin and analyzed by SDS-PAGE and
Western blot. Standard Western blotting was performed using the
rabbit polyclonal antibodies and a mouse anti-his monoclonal
antibody (Clontech).
Detection of GPCMV glycoproteins in GPCMV-infected ﬁbroblast
cells. Conﬂuent ﬁbroblast cells were infected at an MOI of ~2 and
cell lysates were made at 48 hpi in 1 TBS buffer (pH 7.5)
supplemented with 1 mM MgCl2, 50 mM CaCl2, Complete, EDTA-
free Mini protease inhibitor cocktail tablet from Roche, and 1%
Triton X-100. Western blot analysis was performed using the
rabbit peptide antibodies. An uninfected cell lysate was included
as a negative control.
Co-immunoprecipitations of the baculovirus-produced GPCMV
pentamer complex. Immunoprecipitation experiments were per-
formed with a mouse monoclonal anti-guinea pig gH antibody
(394, generated in-house) and rabbit peptide antibodies against
GP129, GP131 and GP133 (described above). The corresponding
negative species control antibodies were a mouse monoclonal
anti-GPCMV gB antibody (29-29) and an irrelevant rabbit anti-
peptide control (derived in-house), respectively. Puriﬁed gH, gL,
GP129, GP131, and GP133 protein was incubated with antibody in
TBS buffer overnight at 4 1C, complexed with protein A/G sephar-
ose beads (Pierce) for 1 h, and washed three times in TBS buffer
containing 1% Triton-X100. The boiled samples were analyzed by
SDS-PAGE/Western blot analysis with the afﬁnity-puriﬁed rabbit
polyclonal antibodies or a mouse-anti-his antibody (Clontech).
Preparation of GPCMV DNA from salivary gland. Guinea pig
salivary gland tissue was homogenized with gentleMACS Disso-
ciator (MACS Miltenyi Biotec) in 5 mL of PBS. Salivary gland
homogenates were centrifuged to remove debris. Two hundred
microliter of the homogenized tissue was used for DNA isolation
with Qiagen DNeasy blood and tissue kit. DNA samples were
analyzed using quantitative PCR.
PCR assays. The copy number of GPCMV DNA was calculated
using a standard curve prepared from a plasmid containing the
target sequence, GP83 (tegument), by quantitative PCR. To normal-
ize the GPCMV DNA copy numbers in a single cell, copy numbers
of the guinea pig β-actin gene were determined by qPCR. TaqMan
primer and probe sets for GP83 and guinea pig β-actin were
designed as previously described (Katano et al., 2007; Nozawa
et al., 2008). Zero Blunt PCR TOPO plasmids (Invitrogen) contain-
ing one copy of the GP83 or guinea pig actin gene were used to
construct standard curves for quantiﬁcation. Ten-fold serial dilu-
tions ranging from 108 to 100 copies per 25 ml reaction volume
were used. Standard curves with 495% ampliﬁcation were used
for determining viral copy number.
To examine the 1.6 kb locus, two PCR approaches were taken as
previously described (Nozawa et al., 2008). First, standard PCR for
detection of the 1.6 kb locus was performed using primers P1 and
M. Auerbach et al. / Virology 441 (2013) 75–8484P2 that span the 1.6 kb region. Second, to quantify the amount of the
1.6 kb (full-length) and the 0.4 kb (deletion) in each sample, qPCR
assays were adapted from the literature (Nozawa et al., 2008). The
ﬁrst primer/probe set targeted a sequence within the GP131 gene,
internal to the 1.6 kb region, (P5, ATAAACGTCGCAGTCCAACGTT, P6,
CGTCCTTCTTGTGGCATTATACG probe F, CACCGTCTTTCATCCGT), and
the second set ampliﬁed the new junction created upon the deletion
of the 1.6 kb region (P7, CGTGTATGAAAATGTGTGGACTGA, P8, TA-
GAAAGGTGCATAATAAACCGTTGA, probe D, TAGAAACGCCC-junction-
AGCATCTTGG). To determine the copy number, the 1.6 kb and 0.4 kb
PCR products generated from the conventional PCR using P1/P2 were
cloned into Zero Blunt PCR TOPO vectors (Invitrogen) and used to
make standard curves. See Fig. 4C for the primer and probe positions.Acknowledgments
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